Search

Your search keyword '"Yamamoto, Yoshiya"' showing total 378 results

Search Constraints

Start Over You searched for: Author "Yamamoto, Yoshiya" Remove constraint Author: "Yamamoto, Yoshiya" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
378 results on '"Yamamoto, Yoshiya"'

Search Results

1. Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment

9. Origin of Pressure-induced Superconducting Phase in K$_{x}$Fe$_{2-y}$Se$_{2}$ studied by Synchrotron X-ray Diffraction and Spectroscopy

13. Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection

14. Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection

17. Usefulness of the Direct and/or Total Bilirubin to Predict Adverse Outcomes in Patients With Acute Decompensated Heart Failure

19. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan

20. Effects of activation of an alcohol metabolic gene, cigarette smoking, and alcohol intake on the incidence of metachronous gastric cancer in patients who underwent endoscopic resection for gastric cancer: A multicenter retrospective pilot study

21. Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation‐related hepatitis

22. Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C

23. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy

26. Red dichromatic imaging improved the visibility of exposed blood vessels in gastric ulcer induced by endoscopic submucosal dissection– a pilot study

27. Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment

33. Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150

34. Add‐on effects of fluvastatin in simeprevir/pegylated‐interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study

35. Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus‐infected patients with renal impairment

36. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C

37. FEASIBILITY OF A NEW LIGATION USING THE DOUBLE-LOOP CLIPS TECHNIQUE WITHOUT AN ADHESIVE AGENT FOR ULCERATION AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION OF THE COLON

40. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B

43. Long-term outcomes and risk factors of recurrent biliary obstruction after permanent endoscopic biliary stenting for choledocholithiasis in high-risk patients

47. Genomic profiling of intestinal/mixed‐type superficial non‐ampullary duodenal epithelial tumors

48. Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria

49. Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions

50. Electronic and crystal structures of LnFeAsO1−x H x(Ln = La, Sm) studied by x-ray absorption spectroscopy, x-ray emission spectroscopy, and x-ray diffraction: II pressure dependence

Catalog

Books, media, physical & digital resources